{\rtf1\ansi\ansicpg1252\cocoartf949\cocoasubrtf430
{\fonttbl\f0\froman\fcharset0 TimesNewRomanPSMT;\f1\fswiss\fcharset0 ArialMT;}
{\margl1800\margr1600\margt500\margbl1440}
{\pard\sa900\fs50\f0\i Media Release\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 Basel, 20 September 2007\line \line {\b European 
licence for Roche HIV drug Viracept recommended for re-instatement} \line Measures put 
in place to restart the manufacturing and supply of HIV medicine\line \line Roche 
announced today that the European Medicines Agency\u8217?s (EMEA) Committee for Human Medicinal Products (CHMP) 
has recommended that Viracept\u8217?s marketing authorization is re-instated in Europe following its suspension 
earlier this summer. The Committee stated that it is satisfied with the actions taken by Roche. The 
positive recommendation is an important step towards lifting the suspension of the marketing authorization 
and will now go to the EU Commission for a final decision. Roche fully intends to re-supply Viracept 
(nelfinavir) once the suspension is lifted. However, it may take a few months for Viracept to be available 
again to prescribers and patients.\line \line Viracept\u8217?s license was suspended in 
August this year following the discovery that some of the drug batches contained a substance called 
ethyl mesylate (EMS).\line \line \u8220?From the beginning of the recall, Roche acted 
responsibly, quickly and always in the best interests of patients. In a situation such as this, the 
most prudent action was to recall the medication\u8221? said William M. Burns, CEO of Roche\u8217?s Pharmaceutical 
Division \u8220?We have worked tirelessly with the health authorities, physicians, health care providers, 
NGO treatment providers and, of course, patient groups on the recall with the full intention of re-supplying 
this medication.\u8221? \line \line The Viracept recall affects those countries where 
Roche-made Viracept is sold or distributed. This excludes the US, Canada and Japan where Pfizer has 
the responsibility to make and distribute Viracept. \line \line {\b About 
Viracept} \line Viracept (nelfinavir), a protease inhibitor is supplied by Roche outside 
the US, Canada and Japan. Viracept was first introduced by Roche in 1999. \line \line {\b About 
Roche} \line Headquartered in Basel, Switzerland, Roche is one of the world\u8217?s leading 
research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world\u8217?s 
biggest biotech company and an innovator of products and services for the early detection, prevention, 
diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people\u8217?s 
health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and 
transplantation, a market leader in virology and active in other major therapeutic areas such as autoimmune 
diseases, inflammation, metabolism and central nervous system. In 2006 sales by the Pharmaceuticals 
Division totaled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion 
Swiss francs. Roche employs roughly 75,000 worldwide and has R&D agreements and strategic alliances 
with numerous partners, including majority ownership interests in Genentech and Chugai. Roche\u8217?s Diagnostics 
Division offers a uniquely broad product portfolio and supplies a wide array of innovative testing products 
and services to researchers, physicians, patients, hospitals and laboratories world-wide. For further 
information, please visit our website at www.roche.com (http://www.roche.com). \line \line {\pard\f0\li0\ri0\sa360\sl360\fs18 All 
trademarks used or mentioned in this release are protected by law.\par}\par}
{\pard \par}
{\pard\sb180\f1\fs22 {\b F. Hoffmann-La Roche Ltd}\line 4070 Basel\line Switzerland \par}
{\pard\sb180\f1\fs22 Corporate Communications\line Roche Group Media Relations \par}
{\pard\sb180\f1\fs22 Tel. +41 61 688 88 88\line Fax +41 61 688 27 75\line www.roche.com \par}
}